nasdaqtlry
Cannabis stocks have gone parabolic. Tilray Brands (TLRY) stock jumped by over 39% on Tuesday while Canopy Growth (CGC) soared by over 78%. SNDL soared by over 22% while the AdvisorShares Pure US Cannabis ETF (MSOS) roared back by over 24.8%. Tilray Brands vs MSOS vs SNDL vs Aurora Cannabis US to reclassify cannabisThese stocks jumped after the Biden administration said that it would reclassify cannabis into a less harmful category. That will be a big step for the cannabis industry, which has come under intense pressure in the past few years. Chuck Schumer, the head of the Senate wrote: “It is...
Invezz
Global pharmaceutical medical cannabis company Tilray Inc (NASDAQ:TLRY) experienced extraordinary volatility towards the end of last week with shares rallying 30.8% on Thursday to $3.90 following commentary from President Biden before erasing most gains and falling -18.7% on Friday after releasing first quarter results with the stock closing at $3.17. Tilray, along with the rest of the Cannabis sector received a boost of investor buying after President Joe Biden on Thursday announced that he had pardoned all people formerly convicted of federal marijuana possession. Tilray rose as high as $3.9...
ValueWalk
Cronos Group (NASDAQ:CRON) had an eventful Q1. The company’s revenues surged 25.05M, or up 98.5% YoY. Other fundamentals for the stock were also clearly in the green, with net income up 79.77% and diluted EPS up 79.55%. The company’s strong prior performance could be an indication that it will keep this trend moving forward and post a positive earnings card for Q2’22 that’s scheduled for August 9. Q2 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorWhen Cronos Group's Q1 results were announced this year the company's shares increased 14% after it beat revenue est...
ValueWalk
Tilray (TLRY) stock jumps on strong earnings and an expanded addressable market Following a torrential implosion of market value since February last year, cannabis firm Tilray (NASDAQ:TLRY, TSE:TLRY) finally gave its stakeholders a reason to smile. Management reported encouraging developments for its fiscal year 2022, including double-digit revenue growth and expectations to be cash flow positive in FY 2023. Further, Switzerland legalizing medical marijuana theoretically expands the total addressable market for cannabis companies. Tilray in particular specializes in exploring the therapeutic p...
ValueWalk
Information about the bill, analyst commentary and a popular weed stock with retail investors Cannabis Stocks RiseCannabis stocks rose Thursday after Bloomberg reported that Senate Democrats plan to introduce legislation decriminalizing the popular and widespread plant’s use. The report said Senate Majority Leader Chuck Schumer and fellow democrats Cory Booker and Ron Wyden planned to introduce the Cannabis Administration and Opportunity Act. Q2 2022 hedge fund letters, conferences and more That sent weed stocks across the US and Canada higher with welcome relief after widespread losses that h...
ValueWalk
Bubble is a dirty word. Most investors think bubbles should be avoided at all costs, but the truth is: Buying stocks in the early stages of a bubble can be very profitable. Consider the cannabis bubble. Back in 2017, marijuana stock Tilray Brands (NASDAQ:TLRY) went from just over $20 per share to over $200 in two months! Q1 2022 hedge fund letters, conferences and more Source: StockCharts It went on to crash more than 90% in less than two years. More recently, the same thing played out with “battery tech” techs. Quantumscape Corp (NYSE:QS) skyrocketed from $10 per share to over $130 between Au...
ValueWalk
Whitney Tilson’s email to investors discussing his presentation this morning at the Benzinga Cannabis Capital Conference. Whitney Tilson’s Presentation At The Benzinga Cannabis Capital ConferenceI flew down to Miami yesterday – my first flight without a mask in more than two years! – to attend the Benzinga Cannabis Capital Conference. Q1 2022 hedge fund letters, conferences and more But I don't have to use or even like the product to like the sector... I think legal marijuana consumption is going to continue to grow at a high rate for many years to come, driven by increasing acceptance among t...
ValueWalk
Medical and consumer cannabis producer Tilray (NASDAQ:TLRY) stock has been an abysmal performer as shares collapsed to a low of $4.78 from its high of $300 after its IPO in September of 2018. The speculation of federal marijuana legalization and profitability initially drove up shares, but the reality of neither occurring for three-years has caused shares to deflate. Incidentally, the Company surprised investors by reporting a profit in its latest earnings report as the pursuit of federal legalization receives another push. Tilray was successful in reaching its target $80 million in synergies ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら